List of Excipients in Branded Drug PANTOPRAZOLE SODIUM DELAYED-RELEASE

Generic Drugs Containing PANTOPRAZOLE SODIUM DELAYED-RELEASE

Company	Ingredient	NDC	Excipient
Preferred Pharmaceuticals Inc	pantoprazole sodium delayed-release	68788-8542	AMMONIA
Preferred Pharmaceuticals Inc	pantoprazole sodium delayed-release	68788-8542	BUTYL ALCOHOL
Preferred Pharmaceuticals Inc	pantoprazole sodium delayed-release	68788-8542	CALCIUM STEARATE

What are the Most Frequently-Used Excipients in PANTOPRAZOLE SODIUM DELAYED-RELEASE?

# Of NDCs	Excipient
2	AMMONIA
2	BUTYL ALCOHOL
2	CALCIUM STEARATE

Pantoprazole Sodium Delayed-Release: Excipient Strategy, Formulation Barriers and Commercial Opportunities

Last updated: August 12, 2026

Pantoprazole sodium delayed-release is a mature proton-pump inhibitor with extensive generic competition and limited remaining composition-of-matter exclusivity. Commercial opportunity has shifted from basic active-ingredient supply to differentiated excipient systems, stable enteric protection, pediatric and geriatric delivery, manufacturing efficiency, and alternative dosage forms. The principal formulation challenge is protecting acid-labile pantoprazole from gastric degradation while releasing the drug rapidly in the intestinal environment.

What excipient strategy is required for pantoprazole sodium delayed-release?

Pantoprazole sodium requires a formulation that controls three risks: chemical degradation in acidic conditions, incompatibility with acidic excipients, and delayed or incomplete intestinal release.

The core excipient strategy generally includes:

1. An alkaline stabilizing system.
2. A low-moisture tablet core.
3. A film barrier between the drug-containing core and the enteric coat.
4. An enteric polymer that resists gastric fluid and dissolves above the target intestinal pH.
5. A coating process capable of maintaining uniformity at low drug loading.

Pantoprazole is acid-labile. Acid exposure can produce degradation products before absorption, reducing dose delivery and potentially affecting impurity profiles. The formulation therefore needs an alkaline microenvironment, commonly created with sodium carbonate or another pharmaceutically acceptable alkaline agent.

A commercial formulation must also control water activity. Moisture can accelerate degradation, alter tablet mechanical properties, and impair enteric-coat performance. Excipient selection, granulation conditions, coating temperature, packaging, and desiccant use are interdependent.

Which excipients are most important?

Formulation function	Typical excipient category	Commercial purpose
Alkaline stabilization	Sodium carbonate or comparable alkalizer	Raises microenvironmental pH and protects pantoprazole
Dilution and tablet structure	Mannitol, lactose-free fillers, microcrystalline cellulose	Provides bulk, compressibility and dose uniformity
Disintegration	Crospovidone or croscarmellose sodium	Promotes rapid release after enteric dissolution
Binding	Povidone or hydroxypropyl cellulose	Improves granule and tablet strength
Lubrication	Calcium stearate or magnesium stearate	Supports compression and ejection
Barrier film	Hypromellose or related film former	Separates alkaline drug core from acidic enteric polymer
Enteric protection	Methacrylic acid copolymers or hypromellose phthalate	Prevents gastric release and enables intestinal release
Coating processing	Talc, polysorbate 80, sodium lauryl sulfate or plasticizers, depending on system	Improves suspension stability, wetting and film formation
Packaging protection	High-barrier blister, bottle, desiccant	Limits moisture and protects shelf life

The exact excipient combination varies by manufacturer. FDA’s Inactive Ingredient Database can support precedent analysis, but it does not establish that every listed excipient is suitable at every concentration or in every dosage form.[1]

How does the pantoprazole formulation protect the active ingredient?

The most defensible formulation architecture uses a layered system:

• Drug-containing alkaline core.
• Seal coat or subcoat.
• Enteric coating.
• Optional polishing or protective overcoat.

The alkaline core is the primary chemical-stability layer. Sodium carbonate is commercially attractive because it is inexpensive, widely available, and familiar to regulators. The level must be balanced against tablet size, alkalinity-related incompatibilities, dissolution behavior, and patient tolerability.

The subcoat reduces direct contact between the alkaline core and the enteric polymer. This is important because some enteric polymers contain acidic functional groups that can interact with pantoprazole or destabilize the active ingredient. A seal coat can also improve coating adhesion and reduce migration of soluble ingredients.

The enteric layer must meet acid-stage and buffer-stage dissolution requirements. Over-coating can delay release beyond the intended window, while under-coating can cause premature gastric release. The coating process must control weight gain, spray rate, atomization, inlet temperature, product temperature, and curing conditions.

What technical barriers affect generic manufacturing?

The main manufacturing barriers are process-control problems rather than access to proprietary chemistry.

Critical variables include:

• Pantoprazole particle size and polymorphic or solid-state behavior.
• Distribution of the alkalizer throughout the core.
• Granule moisture and residual solvent.
• Tablet porosity and tensile strength.
• Subcoat continuity.
• Enteric-coat weight gain and uniformity.
• Dissolution after acid exposure.
• Stability under accelerated and long-term conditions.
• Impurity formation during processing and storage.

A formulation can pass initial dissolution testing and still experience stability failure if moisture protection is inadequate. The most valuable excipient know-how therefore often resides in process parameters, not in the identity of a single excipient.

What formulations are protected or differentiated by excipient design?

Basic pantoprazole delayed-release tablets are difficult to differentiate because multiple manufacturers can use established enteric polymers and alkaline stabilization systems. Stronger commercial positioning comes from dosage forms that solve a specific administration problem.

Conventional delayed-release tablets

These are the largest and most commoditized segment. Differentiation may come from:

• Smaller tablet size.
• Improved swallowability.
• Lower tablet weight.
• Robust stability without a desiccant.
• Lower-cost aqueous coating.
• Reduced friability and better packaging efficiency.
• Scored or unit-dose presentations where permitted.

Any formulation claim must provide a meaningful technical limitation. A patent directed only to routine substitution of one standard film former for another may face validity and obviousness challenges.

Delayed-release oral suspension

Pantoprazole delayed-release oral suspension creates more substantial formulation complexity. The product must maintain drug stability after reconstitution or dispersion, provide accurate dosing, and preserve delayed-release behavior.

Relevant excipient opportunities include:

• Suspending agents.
• Wetting agents.
• Buffering systems.
• Taste-masking agents.
• Particle-size control.
• Unit-dose sachet excipients.
• Reconstitution vehicles.
• Low-moisture powder systems.

The oral suspension format is commercially relevant for patients who cannot swallow tablets, including pediatric and certain hospital populations. FDA labeling for pantoprazole products identifies delayed-release oral suspension as a distinct dosage form with administration instructions that differ from tablets.[2]

Pediatric and geriatric formulations

Pediatric development requires more than reducing tablet size. The product must address dose flexibility, taste, swallowing, dosing-device accuracy, and age-appropriate excipients.

Potential formats include:

• Multiparticulate granules.
• Enteric-coated pellets.
• Sachets.
• Sprinkle products.
• Dispersible systems with protected particles.
• Low-volume suspensions.

The central technical problem is protecting each particle or pellet from gastric acid while preventing dose loss during administration. Multiparticulate systems can support flexible dosing, but they add complexity in coating uniformity, segregation, and packaging.

What is the FDA regulatory status of pantoprazole sodium delayed-release?

Pantoprazole sodium delayed-release products are approved prescription proton-pump inhibitor products in the United States. Protonix, the reference product, was approved as a delayed-release tablet and later supported additional dosage forms, including delayed-release oral suspension.[2]

Generic applicants typically rely on the Abbreviated New Drug Application pathway. The regulatory package must demonstrate pharmaceutical equivalence and bioequivalence, with dissolution performance particularly important for an enteric dosage form.

Relevant regulatory issues include:

• Same active ingredient and dosage form.
• Equivalent strength.
• Comparable release characteristics.
• Compliance with acid-stage and buffer-stage dissolution.
• Acceptable inactive ingredients and levels.
• Stability and impurity control.
• Appropriate labeling and administration instructions.

FDA’s guidance on orally administered delayed-release dosage forms and product-specific recommendations should be reviewed when developing a new generic or reformulated product.[3]

What is the Orange Book status of pantoprazole sodium delayed-release?

Pantoprazole sodium delayed-release tablets and oral suspension are mature products listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.[4]

The commercial implication is significant:

• Reference-product exclusivity is no longer the principal barrier.
• Multiple therapeutically equivalent generic products compete on price and supply reliability.
• Patent risk is generally lower than for recently approved proton-pump inhibitors.
• Formulation-specific patents can still affect individual products.
• ANDA applicants must evaluate listed patents and certification obligations before launch.

Orange Book analysis should be performed at the product level because tablet and oral suspension listings may have different patent histories and regulatory identifiers.

When does pantoprazole lose exclusivity?

Pantoprazole’s core market exclusivity has expired, and generic competition is established. The relevant commercial question is no longer whether basic pantoprazole sodium delayed-release tablets can be copied. It is whether a new product has a sufficiently differentiated dosage form, manufacturing advantage, or channel strategy to earn acceptable margins.

Potential residual barriers include:

• Product-specific formulation patents.
• Method-of-use patents.
• Regulatory exclusivity associated with a later dosage form.
• Trade secrets involving coating and stability processes.
• Device or packaging rights.
• Contractual supply arrangements.

For a current launch decision, patent and exclusivity records should be checked against the FDA Orange Book, USPTO records, FDA approval letters, and active litigation dockets.[4,5]

What patent litigation and Paragraph IV risks affect pantoprazole?

Patent litigation risk is generally concentrated in two areas:

1. A new branded formulation or delivery system that claims a specific excipient architecture.
2. A generic applicant challenging a listed formulation or method-of-use patent.

A Paragraph IV certification may trigger litigation if the patent holder sues within the statutory period. For a mature active ingredient, the risk is usually product-specific rather than molecule-wide.

A strong patent position would normally require claims directed to:

• Defined alkaline-core ratios.
• Specific enteric-layer structures.
• Narrow dissolution profiles linked to formulation parameters.
• Stable oral suspensions with defined particle or polymer systems.
• Improved impurity control.
• Manufacturing processes that produce measurable product advantages.
• Pediatric administration systems.

Broad claims covering routine enteric coating or conventional alkalizers are more vulnerable to prior-art and obviousness attacks. The commercial value of a formulation patent depends on whether competitors can design around the claimed excipient ranges without sacrificing stability or dissolution.

How strong is the pantoprazole patent estate?

The basic pantoprazole patent estate is weak as a barrier to generic tablets because the product is mature and widely supplied. A new patent estate can be stronger when it protects a difficult-to-reproduce formulation or a clinically useful administration advantage.

Patent strategy	Relative strength	Commercial assessment
Basic pantoprazole composition	Low	Expired or commercially exhausted for generic competition
Conventional enteric tablet	Low to moderate	Limited differentiation unless linked to unexpected stability or dissolution
Specific layered coating system	Moderate	Stronger if design-around requires new process development
Oral suspension	Moderate to strong	Higher value where pediatric or swallowing needs are addressed
Multiparticulate sprinkle formulation	Moderate to strong	Potential for pediatric and hospital positioning
Manufacturing impurity-control process	Moderate	Valuable as trade secret; patent strength depends on measurable product benefit
Packaging-only protection	Low to moderate	Useful commercially but vulnerable to substitution

What commercial opportunities exist for excipients and formulation suppliers?

The largest opportunity is not selling a commodity excipient into an undifferentiated tablet. It is supplying an integrated formulation platform that reduces development and manufacturing risk.

Excipient suppliers

Suppliers can target:

• Prequalified enteric polymer systems.
• Ready-to-use aqueous coating dispersions.
• Low-moisture alkaline excipient blends.
• Direct-compression grades.
• Functionalized excipients for suspension and taste masking.
• Film-coating systems optimized for low-temperature processing.
• High-barrier packaging combinations.

A ready-to-use coating system can reduce development time and improve batch-to-batch consistency. The supplier must still support regulatory documentation, elemental impurity information, residual solvent data, nitrosamine risk assessment, and global compendial compliance.

Contract development and manufacturing organizations

CDMOs can compete through:

• Multiparticulate coating capacity.
• Small-batch pediatric development.
• Flexible oral suspension filling.
• High-throughput tablet coating.
• Stability-indicating analytical methods.
• Scale-up experience with alkaline cores.
• Global regulatory support.

The most defensible CDMO proposition is an integrated package covering formulation, process development, analytical validation, registration batches, and commercial supply.

Branded-generic manufacturers

Branded-generic companies can pursue:

• Pediatric and geriatric products.
• Hospital-focused unit-dose products.
• Better adherence through smaller tablets.
• Retail packaging with lower moisture sensitivity.
• Combination therapy positioning where legally and clinically appropriate.
• Supply reliability in markets affected by shortages.
• Regional products using excipients accepted by local regulators.

The revenue ceiling for standard pantoprazole tablets is constrained by low generic pricing. Higher margins are more likely in differentiated dosage forms, private-label supply, hospital contracts, and markets with limited local manufacturing.

How does pantoprazole compare with omeprazole and esomeprazole?

Pantoprazole competes with omeprazole, esomeprazole, lansoprazole and rabeprazole. All require protection from gastric acid, but their formulation and market positions differ.

Attribute	Pantoprazole	Omeprazole	Esomeprazole
Product maturity	Mature generic market	Mature generic market	Mature but often stronger branded positioning
Main formulation issue	Acid-labile active and enteric release	Acid-labile active and enteric release	Acid-labile active and enteric release
Differentiation potential	Oral suspension, hospital supply, pediatric formats	Broad dosage-form competition	Premium branding and formulation extensions
Generic price pressure	High	Very high	High, with some branded exposure
Excipient opportunity	Layered coatings, suspension, multiparticulates	High-volume cost optimization	Specialty formulations and patient convenience
Patent barrier for basic tablets	Low	Low	Low for mature products

Pantoprazole can be attractive where hospital use, intravenous-to-oral conversion, or institutional procurement creates demand for reliable supply. It is less attractive as a stand-alone commodity tablet without a cost or channel advantage.

What generic launch scenarios exist?

Low-cost conventional tablet

This strategy uses standard excipients, high-volume production, and aggressive pricing. It has the lowest technical risk but also the weakest margin potential.

Differentiated oral suspension

This strategy targets pediatric, geriatric, and swallowing-limited patients. Development cost is higher, but competition is narrower and clinical utility is clearer.

Multiparticulate or sprinkle product

This approach can create a more defensible formulation and support flexible dosing. Manufacturing and stability costs are higher than for tablets.

Regional branded generic

A manufacturer can combine a standard formulation with strong distribution, local packaging, and hospital contracting. The patent barrier is limited, but commercial execution becomes the primary differentiator.

What geographic coverage matters?

The United States has a mature ANDA market and strong price competition. Europe, Japan, Canada, Australia and emerging markets have separate regulatory requirements, excipient standards, and patent landscapes.

Geographic formulation considerations include:

• Regional acceptance of excipients.
• Different dissolution specifications.
• Local pediatric requirements.
• Climate-zone stability, especially hot and humid markets.
• Packaging availability.
• Language-specific administration instructions.
• Local patent term and supplementary protection certificate records.
• Import and supply-chain restrictions.

A formulation optimized for the United States may require packaging or excipient changes for tropical markets. Moisture-resistant blister systems and validated stability programs can create a practical advantage in those regions.

Key Takeaways

• Pantoprazole sodium delayed-release requires an alkaline core, moisture control, barrier coating and enteric protection.
• Sodium carbonate and enteric polymers are established formulation tools, so basic excipient substitution has limited patent value.
• The strongest commercial opportunities are delayed-release oral suspension, multiparticulate products, pediatric dosing and hospital-oriented supply.
• Standard tablets face intense generic price competition.
• Formulation patents are more defensible when they claim measurable stability, dissolution, impurity or administration advantages.
• FDA Orange Book and Paragraph IV review remains necessary for each specific dosage form and product.
• Excipient suppliers can capture value through integrated coating systems, alkaline blends and regulatory support rather than commodity materials alone.
• Geographic opportunities depend on excipient acceptability, climate stability, packaging and local patent status.

FAQs

Can pantoprazole sodium delayed-release tablets use lactose?

They can, but lactose compatibility must be assessed against the selected alkaline system, moisture conditions and stability profile. A lactose-free formulation may simplify positioning for manufacturers targeting sensitive patient populations or specific markets.

Is sodium carbonate essential in pantoprazole delayed-release?

No. It is a common stabilizing approach, but alternative alkaline systems may be evaluated if they provide adequate chemical stability, dissolution and manufacturability.

Is an enteric coating required for pantoprazole?

For a conventional delayed-release oral product, gastric protection is central to the dosage-form design. The selected coating must resist acidic conditions and release the drug under intestinal conditions.

Are pantoprazole oral suspensions commercially more attractive than tablets?

They can be, because they address swallowing and pediatric dosing needs. The opportunity is offset by greater development complexity, stability requirements and packaging costs.

Can a new pantoprazole excipient combination receive patent protection?

Potentially, if the claimed combination produces a non-obvious and measurable technical effect, such as improved stability, reduced impurities, reproducible dissolution or a clinically useful administration advantage. Routine substitution of known excipients is less likely to provide durable protection.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (n.d.). Protonix (pantoprazole sodium) prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/